alpha,alpha-Dimethyl-2-quinoxalineacetic acid | 1057395-85-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: alpha,alpha-Dimethyl-2-quinoxalineacetic acid
• 英文别名: 2-methyl-2-quinoxalin-2-ylpropanoic acid
• CAS: 1057395-85-3
• 化学式: C₁₂H₁₂N₂O₂
• 分子量: 216.24
• InChiKey: DKQIQVWPNVRYTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
  申请人：Rohde J. Jeffrey

  公开号：US20060149070A1

  公开（公告）日：2006-07-06

  The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明进一步涉及利用11-β-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由过度糖皮质激素作用介导的疾病和症状。
• INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
  申请人：Rohde J. Jeffrey

  公开号：US20070179186A1

  公开（公告）日：2007-08-02

  The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及使用11-β-羟基类固醇脱氢酶1型酶抑制剂治疗非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合症和其他由过度糖皮质激素作用介导的疾病和病症。
• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Bitner R. Scott

  公开号：US20120289512A1

  公开（公告）日：2012-11-15

  The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

  本发明涉及11-β-羟基类固醇脱氢酶1型酶的抑制剂及其在治疗非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征、中枢神经系统疾病以及与过度糖皮质激素相关的疾病和病症中的应用。
• US7217838B2
  申请人：——

  公开号：US7217838B2

  公开（公告）日：2007-05-15
• US7528282B2
  申请人：——

  公开号：US7528282B2

  公开（公告）日：2009-05-05